Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | HTR6 | P50406 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349109 | 0.90 | SLC6A4 (0.58) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL31421736 | 0.82 | HTR2A (0.61) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL8999077 | 0.82 | HTR2A (0.61) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL347688 | 0.81 | MEN1 (0.62) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| Tryptamine SCHEMBL27810114 | 0.81 | HTR2A (0.86) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL5513682 | 0.79 | HTR2A (0.67) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL6805445 | 0.79 | HTR2A (0.57) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL7005718 | 0.79 | HTR2A (0.71) | HTR2ACYP3A4HTR2CHTR6CYP1A2 | |
| SCHEMBL7004146 | 0.79 | HTR2A (0.71) | HTR2ACYP3A4HTR2CHTR6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | claimed |
| CN-108350034-B | Antimicrobial polymyxin derived compounds | 莫纳什大学 | 2022-03-11 | — | — | CN | claimed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | claimed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | MONASH UNIVERSITY (AU) | 2018-10-04 | — | — | US | claimed |
| EP-3356387-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | Monash University (AU) | 2018-08-08 | — | — | EP | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| CN-101845091-A | Metastin derivative and use thereof | TAKEDA PHARMACEUTICAL | 2010-09-29 | — | — | CN | claimed |
| EP-0410989-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1991-02-06 | — | — | EP | claimed |
| US-4935492-A | Cyclic analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1990-06-19 | — | — | US | claimed |
| WO-1989009611-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-10-19 | — | — | WO | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0323740-A2 | Linear analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1989-07-12 | — | — | EP | claimed |
| WO-1989005654-A1 | LINEAR ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-06-29 | — | — | WO | claimed |
| US-4804650-A | DIURETICS, VASODILATORS | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1989-02-14 | — | — | US | claimed |
| EP-0223143-A2 | Analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1987002674-A1 | ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1987-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | HTR2A 4410/4885CYP3A4 4465/4885HTR2C 4794/4885 |
| US-20180282374-A1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | VIP, PNKP, PEPD | HTR2A 4410/4885CYP3A4 4465/4885HTR2C 4794/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | HTR2A 3852/4885CYP3A4 3635/4885HTR2C 4260/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | HTR2A 3852/4885CYP3A4 3635/4885HTR2C 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.